You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 25, 2026

Claims for Patent: 10,195,205

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,195,205

Title:	Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases
Abstract:	This invention relates to new use of dual NK-1/NK-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.
Inventor(s):	Mike Trower
Assignee:	Kandy Therapeutics Ltd
Application Number:	US15/157,430
Patent Claims:	1. A method of treatment of hot flushes comprising administering to a human in need thereof an effective amount of dual NK-1/NK-3 receptor antagonist 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide of formula (A) or a pharmaceutically acceptable salt thereof 2. A method according to claim 1, wherein the dual NK-1/NK-3 receptor antagonist is the compound of formula (A) as crystalline anhydrate Form 1. 3. A method of treatment of hot flushes comprising: orally administering to a human in need thereof an effective amount of dual NK-1/NK-3 receptor antagonist 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide of formula (A) or a pharmaceutically acceptable salt thereof wherein said orally administering is effective to alleviate symptoms of hot flushes. 4. A method according to claim 3, wherein the dual NK-1/NK-3 receptor antagonist is the compound of formula (A) as crystalline anhydrate Form 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.